Literature DB >> 21462282

Classifying variants of CDKN2A using computational and laboratory studies.

Peter J Miller1, Sekhar Duraisamy, Joan A Newell, Philip A Chan, Mark M Tie, Amy E Rogers, Claire K Ankuda, Genevieve M von Walstrom, Jeffrey P Bond, Marc S Greenblatt.   

Abstract

Variants in the CDKN2A tumor suppressor are associated with Familial Melanoma (FM), although for many variants the linkage is weak. The effects of missense variants on protein function and pathogenicity are often unclear. Multiple methods (e.g., laboratory, computational, epidemiological) have been developed to analyze whether a missense variant is pathogenic or not. It is not yet clear how to integrate these data types into a strategy for variant classification. We studied 51 CDKN2A missense variants using a cell cycle arrest assay. There was a continuum of results ranging from full wild-type effect through partial activity to complete loss of arrest. A reproducible decrease of 30% of cell cycle arrest activity correlated with FM association. We analyzed missense CDKN2A germline variants using a Bayesian method to combine multiple data types and derive a probability of pathogenicity. When equal to or more than two data types could be evaluated with this method, 22 of 25 FM-associated variants and 8 of 15 variants of uncertain significance were classified as likely pathogenic with >95% probability. The other 10 variants were classified as uncertain (probability 5-95%). For most variants, there were insufficient data to draw a conclusion. The Bayesian model appears to be a sound method of classifying missense variants in cancer susceptibility genes.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21462282     DOI: 10.1002/humu.21504

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

Authors:  Allison W Kurian; Emily E Hare; Meredith A Mills; Kerry E Kingham; Lisa McPherson; Alice S Whittemore; Valerie McGuire; Uri Ladabaum; Yuya Kobayashi; Stephen E Lincoln; Michele Cargill; James M Ford
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

2.  Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions.

Authors:  Bryony A Thompson; Marc S Greenblatt; Maxime P Vallee; Johanna C Herkert; Chloe Tessereau; Erin L Young; Ivan A Adzhubey; Biao Li; Russell Bell; Bingjian Feng; Sean D Mooney; Predrag Radivojac; Shamil R Sunyaev; Thierry Frebourg; Robert M W Hofstra; Rolf H Sijmons; Ken Boucher; Alun Thomas; David E Goldgar; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2012-10-22       Impact factor: 4.878

3.  PTENpred: A Designer Protein Impact Predictor for PTEN-related Disorders.

Authors:  Sean B Johnston; Ronald T Raines
Journal:  J Comput Biol       Date:  2016-06-16       Impact factor: 1.479

4.  Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI.

Authors:  Marco Carraro; Giovanni Minervini; Manuel Giollo; Yana Bromberg; Emidio Capriotti; Rita Casadio; Roland Dunbrack; Lisa Elefanti; Pietro Fariselli; Carlo Ferrari; Julian Gough; Panagiotis Katsonis; Emanuela Leonardi; Olivier Lichtarge; Chiara Menin; Pier Luigi Martelli; Abhishek Niroula; Lipika R Pal; Susanna Repo; Maria Chiara Scaini; Mauno Vihinen; Qiong Wei; Qifang Xu; Yuedong Yang; Yizhou Yin; Jan Zaucha; Huiying Zhao; Yaoqi Zhou; Steven E Brenner; John Moult; Silvio C E Tosatto
Journal:  Hum Mutat       Date:  2017-05-16       Impact factor: 4.878

5.  Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.

Authors:  Joshua S Jolissaint; Kevin C Soares; Kenneth P Seier; Ritika Kundra; Mithat Gönen; Paul J Shin; Thomas Boerner; Carlie Sigel; Ramyasree Madupuri; Efsevia Vakiani; Andrea Cercek; James J Harding; Nancy E Kemeny; Louise C Connell; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T Peter Kingham; Alice C Wei; William R Jarnagin
Journal:  Clin Cancer Res       Date:  2021-05-07       Impact factor: 12.531

6.  Microsatellite instability use in mismatch repair gene sequence variant classification.

Authors:  Bryony A Thompson; Amanda B Spurdle
Journal:  Genes (Basel)       Date:  2015-03-30       Impact factor: 4.096

7.  Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Authors:  Mark Harland; Anne E Cust; Celia Badenas; Yu-Mei Chang; Elizabeth A Holland; Paula Aguilera; Joanne F Aitken; Bruce K Armstrong; Jennifer H Barrett; Cristina Carrera; May Chan; Joanne Gascoyne; Graham G Giles; Chantelle Agha-Hamilton; John L Hopper; Mark A Jenkins; Peter A Kanetsky; Richard F Kefford; Isabel Kolm; Johanna Lowery; Josep Malvehy; Zighereda Ogbah; Joan-Anton Puig-Butille; Jordi Orihuela-Segalés; Juliette A Randerson-Moor; Helen Schmid; Claire F Taylor; Linda Whitaker; D Timothy Bishop; Graham J Mann; Julia A Newton-Bishop; Susana Puig
Journal:  Hered Cancer Clin Pract       Date:  2014-11-20       Impact factor: 2.857

8.  Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Authors:  Noah C Jenkins; Jae Jung; Tong Liu; Megan Wilde; Sheri L Holmen; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

9.  Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework.

Authors:  Sarah E Brnich; Ahmad N Abou Tayoun; Fergus J Couch; Garry R Cutting; Marc S Greenblatt; Christopher D Heinen; Dona M Kanavy; Xi Luo; Shannon M McNulty; Lea M Starita; Sean V Tavtigian; Matt W Wright; Steven M Harrison; Leslie G Biesecker; Jonathan S Berg
Journal:  Genome Med       Date:  2019-12-31       Impact factor: 11.117

10.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.